Your browser doesn't support javascript.
loading
Correction: Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease.
Kekre, Natasha; Kim, Haesook T; Hofer, Julia; Ho, Vincent T; Koreth, John; Armand, Philippe; Nikiforow, Sarah; Gooptu, Mahasweta; Romee, Rizwan; Alyea, Edwin P; Nageshwar, Prashant; Glotzbecker, Brett; El-Jawahri, Areej; DeFilipp, Zachariah; Soiffer, Robert J; Antin, Joseph H; Chen, Yi-Bin; Cutler, Corey.
Afiliação
  • Kekre N; Division of Hematology, The Ottawa Hospital, Ottawa, ON, Canada.
  • Kim HT; Department of Data Sciences, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA, USA.
  • Hofer J; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Ho VT; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Koreth J; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Armand P; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Nikiforow S; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Gooptu M; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Romee R; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Alyea EP; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Nageshwar P; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Glotzbecker B; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • El-Jawahri A; Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA.
  • DeFilipp Z; Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA.
  • Soiffer RJ; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Antin JH; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Chen YB; Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA.
  • Cutler C; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. corey_cutler@dfci.harvard.edu.
Bone Marrow Transplant ; 56(5): 1217, 2021 May.
Article em En | MEDLINE | ID: mdl-33041331
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Bone Marrow Transplant Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Bone Marrow Transplant Ano de publicação: 2021 Tipo de documento: Article